ArticleJournal of the International AIDS Society2023
Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.
Article in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Interest in and Preference for Long-Acting Injectable Pre-exposure Prophylaxis Among Men Who Have Sex With Men, Trans* Individuals, and Cisgender Heterosexual Women: A Global Systematic Review and Meta-Analysis.Journal of acquired immune deficiency syndromes (1999) · 2025Pooled it
- Barriers and Facilitators Along the PrEP Continuum of Care Among Latinx Sexual Minoritized Men and Transgender Women: A Systematic Review.AIDS and behavior · 2024Pooled it
- Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.Journal of acquired immune deficiency syndromes (1999) · 2025Trial
- The Role of Healthcare-Related Experiences in Willingness and Preference for Long-Acting Injectable PrEP (LAI-PrEP) Among Transfeminine People in the United States.AIDS and behavior · 2026Article
- Interest in Long-Acting PrEP by Methamphetamine Use Among Men Who Have Sex with Men in Four Western US Cities.AIDS and behavior · 2026Article
- Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.JAMA network open · 2026Article
- How Do Open-Ended Interview and Closed-Ended Questionnaire Responses Compare? A Matched Mixed-Methods Study Examining Treatment Attitudes of Patients With Meniscal Tear and Persistent Pain.ACR open rheumatology · 2026Article
- Developing and assessing acceptability of a shared decision-making tool for selecting among HIV pre-exposure prophylaxis options in the United States of America.PLOS global public health · 2026Article
- Early experiences with usage of long-acting injectable cabotegravir among adults in rural Ugandan and Kenyan communities: qualitative research from the SEARCH "Dynamic Choice HIV Prevention" intervention trials.Journal of the International AIDS Society · 2025Article
- Opinions and Concerns Surrounding Long-Acting Injectable (LAI) and Oral HIV Pre-exposure Prophylaxis (PrEP) Among Current and Former LAI and Oral PrEP Users.AIDS and behavior · 2025Article
- Willingness to Use Long-Acting Injectable Pre-Exposure Prophylaxis among Adolescent Girls and Young Women in Kampala, Uganda.AIDS and behavior · 2025Article
- Preventing Premature Pre-Exposure Prophylaxis Discontinuation and Sexually Transmitted Infections Among Men Who Have Sex With Men (Project PEACH): Protocol for a Prospective Cohort Study.JMIR research protocols · 2025Article
- Willingness to Use Oral and Long-Acting Injectable PrEP in Substance-Using Men who have Sex with Men (SU-MSM) in High HIV Incidence Southern U.S. Cities: A NIDA Clinical Trials Network Study.AIDS and behavior · 2025Article
- Brief communication: attitudes and preferences of long-acting injectable HIV preexposure prophylaxis among Thai adolescents and young adults.AIDS research and therapy · 2025Article
- Long-Acting Injectable Pre-Exposure Prophylaxis Perceptions and Preferences Among Transgender and Nonbinary Young Adults in the United States.Qualitative health research · 2025Article
- Brief Communication: Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university.AIDS research and therapy · 2024Article
- Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.JMIR public health and surveillance · 2024Article
- Transgender Latinas' Perspectives on HIV PrEP Uptake, Condom Use, and Medically Supervised Gender-Affirming Hormone Therapy: Insights From ChiCAS Qualitative Interviews.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024Article
- Brief Report: Interest in Long-acting Injectable PrEP Among Transgender Women in Eastern and Southern United States.Journal of acquired immune deficiency syndromes (1999) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionLong-acting injectable (LAI) pre-exposure prophylaxis (PrEP) for HIV prevention was approved by the U.S. Food and Drug Administration in 2021. LAI PrEP is more effective than oral PrEP. However, it is not clear whether the groups most at risk of HIV in the United States will use LAI PrEP. Willingness to use LAI PrEP and preference for LAI versus oral PrEP has not been reported for sexual and gender minority (SGM) people in the southern United States, where the HIV epidemic is concentrated. Our goal was to assess willingness to use LAI PrEP and preference for oral versus LAI PrEP among SGM people in the southern United States and to assess differences in willingness by demographics and sexual behaviour.
methodsWe conducted an online, cross-sectional survey of SGM people aged 15-34 years in the southern United States (n = 583). Participants reported willingness to use LAI PrEP and preferences for LAI PrEP versus daily oral PrEP. We assessed bivariate associations and adjusted prevalence ratios for the LAI-PrEP-related outcomes and key demographic and behavioural characteristics.
resultsOverall, 68% of all participants (n = 393) reported being willing to use LAI PrEP that provides protection against HIV for 3 months. Of those, most (n = 320, 81%) indicated a preference for using LAI PrEP, compared to a daily oral pill or no preference. Willingness to use LAI PrEP was more common among transgender and non-binary participants and participants who engaged in condomless anal intercourse in the last 6 months. Hispanic participants were more likely and non-Hispanic Black participants were less likely to report willingness to use LAI PrEP compared to non-Hispanic White participants.
conclusionsWillingness to use LAI PrEP was high among SGM people in the southern United States, although there were some important differences in willingness based on demographic characteristics. Decreased willingness to use LAI PrEP among groups who are disproportionately affected by the HIV epidemic, such as non-Hispanic Black SGM people, could exacerbate existing disparities in HIV incidence. LAI PrEP is an acceptable option among SGM populations in the southern United States, but strategies will be needed to ensure equitable implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.